Company: PTPI
Filing Date: 2025-02-19
Form Type: 424B4
Source: 0001410578-25-000164
Chunk: 249

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-19
Form: 424B4
Chunk 249
---
    |    -663,984 |
| Noncash decrease in API purchase commitment                                      | ​ | ​                                       |          — | ​ | ​    |     694,314 |
| Noncash decrease in other current assets: API purchase commitment                | ​ | ​                                       |          — | ​ | ​    |     -30,330 |
| Noncash issuance of common stock to non-employee                                 | ​ | ​                                       |          — | ​ | ​    |           3 |
| Noncash initial fair value of warrant liability pursuant to private placement    | ​ | ​                                       |          — | ​ | ​    |  21,544,000 |
| Noncash initial fair value of derivative liability pursuant to private placement | ​ | ​                                       |          — | ​ | ​    |   6,140,000 |
| Noncash redemption of Series A Preferred Stock                                   | ​ | ​                                       |  6,586,033 | ​ | ​    |           — |
| Accrued Series A Convertible Preferred payments payable                          | ​ | ​                                       |  1,742,918 | ​ | ​    |   1,368,546 |
| Accretion of Series A convertible preferred stock to redemption value            | ​ | ​                                       |  9,099,230 | ​ | ​    |   1,153,846 |
| Accrual of Series convertible preferred stock dividends                          | ​ | ​                                       |    991,783 | ​ | ​    |     339,232 |

The accompanying Notes are an integral part of the Unaudited Condensed Consolidated Financial Statements.

F-36

#### PETROS PHARMACEUTICALS, INC.

### NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
<div align='center'>(Unaudited)</div>

**1) Nature of Operations, Basis of Presentation, Liquidity and Going Concern**

#### Nature of Operations
Petros Pharmaceuticals, Inc. (“Petros” or the “Company”) was incorporated in Delaware on May 14, 2020, for the purpose of effecting the transactions contemplated by that certain Agreement and Plan of Merger, dated as of May 17, 2020 (as amended, the “Merger Agreement”), by and between Petros, Neurotrope, Inc., a Nevada corporation (“Neurotrope”), Metuchen Pharmaceuticals LLC, a Delaware limited liability company (“Metuchen”), and certain subsidiaries of Petros and Neuro